Webinar Recording - The cardiovascular risks and benefits of quit smoking medicines

The National Drug and Alcohol Research Centre (NDARC) recently delivered a webinar titled “The cardiovascular risks and benefits of quit smoking medicines” presented by Dr Alys Havard and Dr Annelies Robijn from NDARC. The webinar reports on the results of three population-based cohort studies relating to the use and effects of smoking cessation pharmacotherapies.

The first study discussed compares cardiovascular safety of three smoking cessation pharmacotherapies available in Australia, nicotine replacement therapy (NRT), varenicline and bupropion. The second study looks at prevalence of use of these products  among people hospitalised for a major cardiovascular disease.  The final study, also based on patients hospitalised for a major cardiovascular disease, compares the effectiveness of  NRT and varenicline in preventing recurrent cardiovascular events.

Watch “Cardiovascular risks and benefits of quit smoking medicines” (55 minutes)